– Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – Company to initiate first clinical trial of MM-402 in 2023 – Cash runway to fund current operating plan into first half of 2025 – Company to host a virtual analyst and investor day in […]
Read MoreYou are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
